Expression of focal adhesion kinase (FAK) is elevated in malignant breast cancer, yet the role of intrinsic FAK activity in promoting tumor progression remains undefined. Here, we have inhibited FAK activity or expression in murine 4T1 breast carcinoma cells via dominantnegative focal adhesion kinase-related non-kinase (FRNK) or anti-FAK short hairpin RNA (shRNA) expression, respectively. Neither FRNK nor FAK shRNA (B80% reduced FAK levels) affected 4T1 proliferation in culture, whereas reduced FAK activity or expression blocked 4T1 cell invasion through Matrigel and resulted in 2-3-fold lower urokinase plasminogen activator (uPA) expression. Control 4T1 cells implanted into mammary fat pads of BALB/c mice exhibited spontaneous metastasis to the lungs, to the peritoneal cavity, and resulted in 90% lethality within 21 days. Whereas FAK shRNAexpressing 4T1 cells formed tumors in mice with low levels of apoptosis, when mammary-injected, these cells did not exhibit lung metastasis after 21 days and caused only 40% lethality up to 60 days. Transient re-expression of wildtype but not kinase-dead FAK in 4T1 FAK shRNA cells promoted uPA production and mammary to lung metastasis within 7 days. In fact, stable human uPA overexpression in 4T1 FAK shRNA cells promoted Matrigel invasion and lung metastasis equal to 4T1 controls. Conversely, treatment with plasminogen activator inhibitor-1 or neutralizing antibody to uPA blocked Matrigel invasion of 4T1 control cells. These studies provide the first direct proof that FAK catalytic activity can facilitate metastatic breast cancer progression by regulating uPA expression.
Introduction
Focal adhesion kinase (FAK) is an intracellular proteintyrosine kinase, the activity of which is regulated by integrin-mediated cell adhesion (Parsons, 2003) . In normal cells, FAK functions as an important regulator of cell motility, proliferation and anchorage-dependent cell survival (Hanks et al., 2003; . In many tumor cells and malignant tissue, FAK expression is elevated (Gabarra-Niecko et al., 2003) and the role of FAK in promoting tumor progression remains an area of active investigation (McLean et al., 2005) .
Overexpression of the FAK C-terminal domain (termed focal adhesion kinase-related non-kinase (FRNK)) inhibits FAK activity and tyrosine phosphorylation in part by disrupting FAK association with integrins. Whereas high levels of FRNK can promote cell apoptosis (Xu et al., 2000; Golubovskaya et al., 2002) , FRNK expression can also reduce tumor growth by promoting tumor dormancy and by inhibiting cell proliferation (Aguirre Ghiso, 2002; van Nimwegen et al., 2005) . Low levels of FRNK expression have revealed the importance of FAK activity in promoting tumor cell migration (Slack et al., 2001) and in generating an invasive cell phenotype (Hauck et al., 2001 (Hauck et al., , 2002b Hsia et al., 2003; .
Despite the effective use of FRNK as an inhibitor of FAK, overexpression of the FAK C-terminal domain encompassing multiple protein binding sites may be associated with effects not related to the inhibition of FAK activity (Almeida et al., 2000) . As strategies using antisense oligonucleotides (Xu et al., 1996; Hauck et al., 2001) or RNA interference (RNAi) (Duxbury et al., 2003; Han et al., 2004) can reduce FAK expression in tumor cells, these methods have not yet been tested for specificity via FAK reconstitution and rescue assays. Only in RNAi-treated normal fibroblasts (Tilghman et al., 2005) and in reconstituted FAK-null (Owen et al., 1999; Sieg et al., 1999) or v-Src-transformed FAK-null fibroblasts (Hsia et al., 2003; Wu et al., 2005) have FAK re-expression and tyrosine phosphorylation been linked to the promotion of cell motility and/or invasion.
Analyses of breast cancer tumor samples have revealed that elevated FAK expression is correlated with the development of benign ductal hyperplasia into invasive carcinomas (Oktay et al., 2003; Lightfoot et al., 2004) . Here, we have inhibited FAK activity or FAK expression in murine 4T1 breast carcinoma cells via transient FRNK or stable anti-FAK short hairpin RNA (shRNA) expression, respectively. 4T1 cells are derived from a spontaneously arising BALB/c mouse mammary tumor, are highly metastatic and are used as a late-stage model for human breast cancer (Aslakson and Miller, 1992; Heppner et al., 2000) . Focal adhesion kinase shRNA expression resulted in the inhibition of 4T1 cell invasion in vitro and spontaneous 4T1 metastasis after orthotopic implantation. Transient wild-type (WT) but not kinase-inactive FAK re-expression in 4T1 FAK shRNA cells promoted in vivo lung metastasis and this was shown to be associated with increased urokinase plasminogen activator (uPA) expression and secretion. As the inhibition of FAK expression within 4T1 cells was also associated with increased host survival after tumor cell implantation, our results support the pharmacological targeting of FAK activity as a means to inhibit metastatic tumor progression.
Results
Focal adhesion kinase-related non-kinase inhibits focal adhesion kinase tyrosine phosphorylation and breast carcinoma cell invasion through Matrigel Tumor cell invasion is facilitated via cell protrusions called invadopodia that are sites of b1 integrin clustering, actin filament assembly and protease secretion (Buccione et al., 2004) . As FAK facilitates invadopodia formation by v-Src (Hauck et al., 2001; Hsia et al., 2003) , we investigated the localization and activity of FAK within murine 4T1 breast carcinoma cells (Figure 1) . 4T1 cells are highly invasive and spontaneously metastasize upon orthotopic implantation in BALB/c mice (Aslakson and Miller, 1992) . Upon plating 4T1 cells onto collagen type I, actin-enriched invadopodia are formed and FAK colocalizes with these protrusive structures ( Figure 1a) . To determine whether FAK activity is regulated by integrins in 4T1 cells, FAKassociated in vitro kinase (IVK) activity was measured from adherent, suspended or fibronectin-replated cells (Figure 1b and c) . Focal adhesion kinase IVK activity was high in serum-starved adherent 4T1 cells and was inhibited 40% when cells were held in suspension for 45 min. Fibronectin re-plating resulted in B2-fold elevated FAK activity compared to suspended cells, suggesting that integrins facilitate FAK activation in 4T1 cells (Figure 1b and c) .
As FAK is targeted to sites of integrin clustering via the FAK C-terminal domain, adenoviral (Ad)-mediated expression of hemagglutinin (HA)-tagged FRNK was used as a dominant-negative inhibitor of FAK activity. As a control, HA-tagged FRNK Ser-1034 (S1034) that contains point mutation disrupting integrin localization (Sieg et al., 1999) was also expressed via recombinant adenovirus. Ad-FRNK was expressed in B90% of 4T1 cells as determined by HA-tag staining (data not shown) and this resulted in B80% reduction in FAK IVK activity (Figure 1b and c) . Importantly, equal expression of Ad-FRNK S1034 had no effect on FAK activity (Figure 1c) , thus supporting the conclusion that integrins facilitate FAK activation in 4T1 cells. As other studies have shown that FRNK can cause cell apoptosis (Xu et al., 1998 (Xu et al., , 2000 , 4T1 cell proliferation assays were performed. Importantly, 80% inhibition of FAK activity by Ad-FRNK (Figure 1b and c) did not affect 4T1 cell proliferation on fibronectin (Figure 1d ) or collagen (data not shown) compared to uninfected 4T1 parental cells or Ad-FRNK S1034-expressing cells. When assayed for serum-stimulated cell motility, FRNK-expressing 4T1 cells showed a slight reduction in cell migration compared to FRNK S1034-expressing cells (Figure 1e ). However, when assayed for serum-stimulated invasion through Matrigel, FRNK-expressing 4T1 cells showed an B80% reduction in invasive motility compared to FRNK S1034-expressing cells (Figure 1f ). In these assays, there was no difference between uninfected 4T1 control and Ad-FRNK S1034-expressing cells (data not shown).
To explore the mechanism through which FRNK may selectively inhibit the 4T1 invasive cell phenotype, gelatin and casein zymography analyses were performed with 4T1-conditioned media to evaluate potential differences in protease secretion. A major B90 kDa and a minor 60 kDa band of gelatinase activity that comigrated with matrix metalloproteinase (MMP)-9 and MMP-2 standards, respectively, were observed in conditioned media from FRNK S1034-expressing 4T1 cells ( Figure 1g ) and an identical profile was observed from 4T1 control cell media (data not shown). High levels of an B42 kDa protease that activated plasminogen to facilitate casein degradation, consistent with the size of uPA, was also detected in the conditioned media from control (data not shown) and FRNK S1034-expressing 4T1 cells (Figure 1g ). Ad-FRNK expression resulted in reduced 90 kDa but not 60 kDa gelatinase activity and in the suppression of uPA activity (Figure 1g ). Together, our results using FRNK suggest that FAK activity may selectively function to promote 4T1 cell invasion.
Stable focal adhesion kinase-specific short hairpin RNA expression inhibits 4T1 invasion through Matrigel but not cell proliferation To establish the connection between FAK and 4T1 cell invasion, lentiviral-mediated shRNA production was used to stably inhibit FAK expression in 4T1 cells (Figure 2 ). The bicistronic recombinant lentivirus expressed anti-FAK shRNA and enhanced green fluorescent protein (GFP) that allowed for the enrichment of FAK shRNA-expressing cells by fluorescenceactivated cell sorting (FACS). Stable pooled populations of FAK shRNA-and empty vector GFP-expressing cells were obtained (Figure 2a ) and B80% reduction in FAK protein expression was achieved compared to 4T1 lentivirus control and 4T1 parental cells (Figure 2b ).
Further enrichment of FAK shRNA-expressing 4T1 cells was not successful, as these cells did not survive after FACS (data not shown). Importantly, B80% knockdown of FAK protein expression did not affect 4T1 cell proliferation on fibronectin (data not shown) or collagen ( Figure 2c ).
To determine whether FAK knockdown affected 4T1 cell survival or growth under anchorage-independent conditions, 4T1 FAK shRNA or control cells were grown in suspension on polyhydroxyethyl methacrylate (HEMA)-coated plates. After 72 h, cell spheroids were dissociated and analysed by FACS after annexin V and 7-amino-actinomycin D (7-AAD) double staining ( Figure 2d ). The loss of FAK expression in 4T1 FAK shRNA cells did not promote cell apoptosis compared to 4T1 control and 4T1 parental cells, whereas staurosporine treatment for 12 h resulted in high levels of annexin V-positive cells, an indicator of apoptotic death (Figure 2d ). Importantly, 4T1 FAK shRNA cells continued to grow in an anchorage-independent manner and formed equal-sized colonies compared to controls after 3 weeks on polyHEMA (Figure 2e) .
When evaluated in a serum-stimulated chemotaxis assay, 4T1 FAK shRNA cell motility was reduced twofold compared to GFP-expressing control and 4T1 parental cells (Figure 2f ). Additionally, FAK shRNA expression also resulted in the inhibition of 4T1 Matrigel invasion by >80% (Figure 2g ). When conditioned media were analysed by gelatin and casein-plasminogen zymography, reduced levels of 90 and 42 kDa zones clearing activity were detected from 4T1 FAK shRNA compared to control 4T1 cells (Figure 2h ). The casein-associated clearing activity was positively identified as uPA by blotting of conditioned media (Figure 2h ). Reverse transcriptase-PCR analyses revealed lower levels of MMP-9 and uPA mRNA levels in 4T1 FAK shRNA cells (Figure 2i ). To determine whether reduced FAK expression alters uPA expression in other cells, human-specific FAK shRNA was stably expressed in MCF-7 and MDA-MB-231 breast carcinoma cells. In MCF-7 cells, >80% reduction in FAK expression was achieved and resulted in the inhibition of uPA expression ( Figure 2j ). In MDA-MB-231 cells, >60% reduction in FAK expression was achieved and this was also associated with reduced uPA expression ( Figure 2k ). Together, these results support the conclusion that FAK expression is important in promoting 4T1 cell invasion and that uPA expression is regulated by FAK in both murine and human breast cancer cell lines. Focal adhesion kinase short hairpin RNA expression in orthotopically implanted 4T1 cells inhibits metastasis and prolongs animal survival To determine whether FAK shRNA inhibition of cell invasion through Matrigel was also associated with alterations in 4T1 tumor growth and metastasis, cells were injected into the T4 mammary fat pad of BALB/c mice ( Figure 3) . Previous studies have shown that 4T1 cells undergo spontaneous metastasis via intravasation into blood vessels after orthotopic implantation into mammary fat pads (Aslakson and Miller, 1992) . Surprisingly, 90% of 4T1 control cell-injected animals died within 3 weeks, whereas only 30% of 4T1 FAK shRNA cell-injected animals died after 21 days (Figure 3a) . Neither 4T1 control nor 4T1 FAK shRNA cells formed a defined solid tumor mass within the mammary area after 3 weeks. Upon autopsy, control 4T1 cells had destroyed tissue structure of the T4 and neighboring mammary fat pads (data not shown). Macroscopic analyses showed significant damage to the peritoneal wall underlying the fat pad area resulting in leakage of peritoneal fluid under the skin. Numerous GFP-positive tumors were found on the external surface of the colon (Figure 3b ), liver and heart (data not shown). Similarly, injection of 4T1 FAK shRNA cells resulted in T4 fat pad tissue destruction and breach of the peritoneal cavity. However, very few GFP-positive 4T1 FAK shRNA tumors were found in the peritoneal cavity (Figure 3b) .
Distant metastases were also observed in lungs of animals injected with control 4T1 cells (Figure 3c ). Lung metastases were accompanied by hemorrhaging and this was associated with a 15-20% increase in lung weight (Figure 3c and d) . Hematoxylin-eosin (H&E) staining revealed the presence of large metastatic nodules in 4T1 control cell-injected mice (Figure 3e ). High-magnification analysis showed that GFP-labeled tumor cells were lining blood vessels, had breached vessel walls and were spreading to bronchiole and alveolar spaces (Figure 3f ). These observations suggest that lung metastases may have arisen from blood-borne tumor cells. Additionally, staining of nucleated Hoechst-positive cells that were not GFP-labeled (Figure 3f ) within lung blood vessels of animals with metastases suggests the presence of immune cell infiltration. In comparison, GFP-labeled tumor cells were not detectable in lungs of mice injected with 4T1 FAK shRNA cells after 21 days and there was no corresponding Hoechst-positive cell staining within lung blood vessels (Figure 3e and f) . Notably, the inhibition of 4T1 cell metastasis by FAK shRNA expression corresponded with the enhancement of animal survival showing only 40% lethality up to 60 days after orthotopic tumor cell injection (Figure 3a) .
Focal adhesion kinase re-expression and catalytic activity are required to promote 4T1 cell metastasis to lungs To prove that the inhibition of 4T1 cell metastasis was due to reduced FAK expression, WT or kinase-inactive FAK (R454 FAK) were re-expressed in 4T1 FAK shRNA cells via recombinant Ad transfection (Figure 4a ). Previous studies showed that 4T1 cell metastasis to lungs can be detected within 7 days (Aslakson and Miller, 1992) . Therefore, 1 week after Ad-FAK re-expressing cells were injected into the T4 mammary fat pad, tumor cell metastasis to the lungs was detected by GFP fluorescence in frozen tissue sections (Figure 4b ). High levels of GFP-expressing 4T1 control cells were observed lining the interior of lung blood vessels. No significant GFP fluorescence was detected in lungs from either mock or Ad-R454 FAK-expressing 4T1 FAK shRNA cells (Figure 4b ). Significantly, WT FAK re-expression promoted 4T1 lung metastasis as detected by GFP fluorescence in lung sections (Figure 4b) , and HA-FAK expression within the metastatic 4T1 FAK shRNA cells was detected by immunoblotting of total lung protein lysates (Figure 4c) .
To examine the mechanism through which Ad-FAK promoted a metastatic phenotype, subcutaneous tumor growth and apoptosis studies were performed. These assays were limited to a short time interval as Ad preinfection of 4T1 cells resulted in tumor regression in both BALB/c and nude mice beyond 7 days (data not shown). Both control and 4T1 FAK shRNA cells formed small subcutaneous tumors in BALB/c mice. Only minor differences in tumor cell apoptosis were observed between 4T1 control and Ad-FAK WT-or Ad-FAK R454-infected 4T1 FAK shRNA cells as determined by TUNEL staining of tumor sections (Figure 4d and e). As Ad-FAK expression did not affect the growth of 4T1 FAK shRNA cells in vitro (data not shown), these results support the conclusion that FAK activity may be affecting the profile of secreted factors that influence tumor metastasis in vivo.
Urokinase plasminogen activator overexpression rescues lung metastasis defect of 4T1 focal adhesion kinase short hairpin RNA cells As 4T1 cells with reduced FAK activity due to FRNK expression (Figure 1g ) or reduced FAK levels ( Figure 2f) showed less protease secretion, we investigated whether transient Ad-FAK WT or Ad-R454 FAK re-expression functioned to reverse the low level of uPA expression in 4T1 FAK shRNA cells (Figure 5a ). Only WT FAK promoted uPA expression as determined by blotting and this result confirms that FAK activity promotes uPA expression in 4T1 cells. To determine whether reduced uPA expression in 4T1 FAK shRNA cells is functionally significant with respect to the role of FAK in promoting cell invasion and metastasis, human uPA (huPA) was stably overexpressed in murine 4T1 FAK shRNA cells (Figure 5b ). The immunoblotting antibody used detects both murine and human uPA, and the level of huPA overexpression was two-and fourfold compared to 4T1 control and 4T1 FAK shRNA cells, respectively. Surprisingly, huPA overexpression was sufficient to rescue the Matrigel invasion defects of 4T1 FAK shRNA cells to a level equal to 4T1 control cells (Figure 5c ). When analysed for mammary to lung metastasis in a 7-day assay, huPA overexpression promoted 4T1 FAK shRNA cell metastasis to blood vessels within the lung (Figure 5d ) and the amount of 4T1 tumor cell burden within the lung was equal to 4T1 control cells as determined by blotting for GFP expression in protein lysates of lung tissue (Figure 5e ). These results show that huPA expression in 4T1 cells with reduced FAK expression is sufficient to reverse the invasion and metastasis defects observed in cells lacking FAK.
To determine whether uPA activity is functionally significant in promoting the parental 4T1 invasive cell phenotype, recombinant mouse plasminogen activator inhibitor-1 (PAI-1) or a uPA inhibitory antibody (1190) was added to 4T1 cells and evaluated in Matrigel invasion assays (Figure 5f ). Plasminogen activator inhibitor-1 or 1190 antibody addition inhibited 4T1 cell invasion by B80-90% compared to untreated 4T1 cells and isotype control immunoglobulin (IgG)-treated 4T1 cells. As uPA overexpression can reverse the invasion and metastasis defects of 4T1 FAK shRNA cells (Figure  5c -e) and inhibition of uPA activity blocks parental 4T1 cell invasion (Figure 5f ), our results support the conclusion that 4T1 cell invasion and metastasis may be largely controlled by FAK signals regulating uPA expression and secretion.
Focal adhesion kinase connections to extracellular signalregulated kinase and JNK regulate urokinase plasminogen activator production Focal adhesion kinase is a multifunctional kinase that can activate a number of different intracellular signaling pathways . To determine the signaling pathways regulating uPA expression, 4T1 cells were treated with inhibitors to c-Src (PP2), JNK1/2 (SP600125), MEK1 (PD98059 and U0126), PI 3-kinase (wortmannin) and p38 MAPK (SB203580) or infected with Ad-FRNK, as pharmacological inhibitors to FAK are not yet available (Figure 5g ). When FAK, c-Src, JNK1/2 and MEK1 were inhibited, uPA expression was reduced whereas inhibitors to PI 3-kinase and p38 MAPK had no effect on uPA levels. Ad-FAK overexpression in 4T1 FAK shRNA cells resulted in elevated extracellular signal-regulated kinase 2 (ERK2) and JNK MAP kinase activation (data not shown), which is consistent with FAK being upstream of ERK and JNK in 4T1 cells. Importantly, expression of FAK mutated at the Y397 phosphorylation and c-Src binding site (F397), kinase-dead FAK mutated within the kinase domain (R454) and FAK mutated at both C-terminal domain proline-rich Src-homology 3 (SH3) binding sites (Pro-null) did not function to promote uPA expression in 4T1 FAK shRNA cells (Figure 5h ). The fact that WT JNK1 and constitutively activated (CA) MEK1 functioned to promote uPA expression in 4T1 FAK shRNA cells supports the conclusion that FAK expression, catalytic activity, Y397 phosphorylation and the SH3 target protein binding sites on FAK contribute to the formation of a signaling complex upstream of ERK and JNK that acts to regulate uPA expression in 4T1 cells.
Discussion
Studies to date implicating the role of FAK in promoting tumor cell invasion and metastasis have been inferred through the use of FRNK expression as an inhibitor of FAK activity. In many cell types, FRNK expression has been shown to block cell motility and invasion through Matrigel Mitra et al., 2005) . In experimental metastasis assays after tail vein injection, FRNK expression in v-Src-transformed fibroblasts (Hauck et al., 2002b) , B16-F10 (AbdelGhany et al., 2002) and MTLn3 breast carcinoma cells (van Nimwegen et al., 2005) blocked tumor cell colonization of lungs. In various tumor cells, exogenous FRNK expression is correlated with reduced levels of protease secretion (Hauck et al., 2002b; Hess et al., 2005) or slower growth (van Nimwegen et al., 2005) . Although FRNK acts to inhibit FAK activity, it also encompasses multiple protein binding sites and may act to sequester signaling proteins away from FAK. Owing to these concerns, recent studies have used RNAi to reduce FAK expression. In human MDA-231 breast carcinoma cells, anti-FAK RNAi resulted in the inhibition of lung metastasis after orthotopic implantation in nude mice (Benlimame et al., 2005) .
Despite the strong correlations between FAK and tumor metastasis, the molecular mechanism(s) through which FAK can promote these events has yet to be established. Here, we show that both transient FRNK or stable anti-FAK shRNA expression did not affect proliferation or survival in cell culture but instead acted to inhibit 4T1 breast carcinoma cell invasion through Matrigel. This was associated with reduced MMP-9 and uPA expression. 4T1 cells are highly aggressive and, upon orthotopic implantation into mammary fat pads of BALB/c mice, exhibit spontaneous metastasis to the lungs, to the peritoneal cavity, which was associated with 90% mouse lethality within 21 days. 4T1 FAK shRNA cells formed tumors in mice with low levels of apoptosis. Yet mammary-injected FAK shRNA 4T1 cells did not exhibit lung metastasis after 21 days and caused only 40% lethality up to 60 days.
To determine how the loss of FAK expression was connected to the inhibition of metastasis, gain-offunction assays were performed. Transient re-expression of WT but not kinase-dead (R454) FAK in 4T1 FAK shRNA cells promoted uPA production and mammary to lung metastasis within 7 days. In fact, stable uPA overexpression in FAK shRNA 4T1 cells promoted Matrigel invasion and lung metastasis equal to 4T1 control cells. These results, along with the fact that PAI-1 and inhibitory anti-uPA antibody addition blocked 4T1 cell invasion, support the importance of this FAK signaling linkage to uPA in promoting an invasive cell phenotype. As increased uPA expression is a marker for breast cancer progression (Weigelt et al., 2005) and recent studies using 55 matched pairs of normal and pathological breast tissue samples revealed increased FAK expression in >90% of the tumor samples (Watermann et al., 2005) , our results provide the first direct proof that FAK catalytic activity is an important mediator of metastatic breast cancer progression via the regulation of uPA expression.
Notably, we found that FAK shRNA expression in 4T1 cells resulted in the reduction of both uPA mRNA and protein expression. Focal adhesion kinase shRNA expression in both human MCF-7 and MDA-MB-231 breast carcinoma cells also resulted in the inhibition of uPA expression. In analysing published gene array data that compared the mRNA profile of benign breast tissue versus breast carcinoma (Sorlie et al., 2001 ) and normal lung tissue versus lung adenocarcinoma (Bhattacharjee et al., 2001) , both FAK and uPA expressions are significantly upregulated in the carcinoma samples. As FAK expression is elevated in a variety of tumor cells and malignant tissues (Gabarra-Niecko et al., 2003) , and FAK re-expression in v-Src-transformed FAKÀ/À fibroblasts promotes uPA expression (S Mitra, unpublished results), our findings support the conclusion that enhanced FAK signaling promotes uPA expression in a variety of cell types and that this signaling linkage contributes to tumor progression.
In addition to the importance of FAK catalytic activity to this signaling linkage, we found that the integrity of the Y397 phosphorylation-SH2 binding site and the C-terminal proline-rich SH3 binding sites in FAK were required to promote uPA expression in FAK shRNA 4T1 cells. As treatment of control 4T1 cells with inhibitors to Src-family PTKs, JNK and MEK1-ERK blocked uPA expression, and previous studies have shown that FAK can promote Src, JNK and ERK activation , it is possible that a multi-protein signaling complex with FAK generates signals to ERK and JNK leading to changes in uPA expression. This conclusion is supported by the fact that v-Src-stimulated cell invasion is linked to the formation of a FAK-Src-p130Cas-Dock180 signaling complex, elevated Rac and JNK activation and increased MMP expression and activity (Hsia et al., 2003) . Further, inhibition of Src and MAPK activation blocks an ErbB2/3 to FAK signaling linkage, promoting cell invasion (Benlimame et al., 2005) . As we found that uPA expression in 4T1 FAK shRNA cells was rescued by constitutively active MEK1 or WT JNK1 expression, it is likely that multiple signaling pathways downstream of FAK contribute to uPA expression, cell invasion and metastasis.
One of the striking features of using 4T1 cells with BALB/c mice in a syngeneic breast carcinoma model is that tumor cell metastasis to the lung can be detected within 1 week after orthotopic injection (Aslakson and Miller, 1992) . In our studies, 4T1 cells injected into the T4 mammary fat pad exhibited two modes of metastasis. First, local invasion of peritoneum was evident in close proximity to the site of injection. Although 4T1 FAK shRNA cells breached the peritoneum in this manner, these cells failed to colonize and grow topically on the colon, liver and heart as did control 4T1 cells. This result suggests that FAK signaling promotes the colonization or survival of 4T1 cells in a foreign stromal environment and that reduced FAK expression did not result in a total invasion defect. Secondly, 4T1 FAK shRNA cells showed little or no distant metastasis compared to control 4T1 cells that readily traversed to the lungs and induced hemorrhagic and inflammatory responses within 3 weeks. As 4T1 mammary to lung metastasis has been shown to involve intravasation to the blood circulation without significant lymph node involvement (Aslakson and Miller, 1992) and our 7-day metastasis assay showed 4T1 tumor cells lining the interior space of lung blood vessels, FAK-induced uPA secretion is likely to play an important role in either intravasation or lung colonization processes. Alterations in uPA expression were shown to be necessary and sufficient for these events, as uPA overexpression in 4T1 FAK shRNA cells promoted lung metastasis. Thus, our results are consistent with a protease-associated role of huPA in promoting both tumor cell intravasation (Kim et al., 1998) and lung colonization (Yu and Schultz, 1990 ) in a mouse model system.
Finally, analyses of FAK expression levels in esophageal squamous cell carcinoma (Miyazaki et al., 2003) , hepatocellular carcinoma (Itoh et al., 2004) , acute myeloid leukemia (Recher et al., 2004) and ovarian cancer (Sood et al., 2004) tissue samples have found that FAK expression levels are inversely correlated with patient survival. As many cancer-related deaths are associated with elevated metastatic tumor burden, it is of interest to note that injection of malignant 4T1 cells expressing high levels of FAK led to the early death of 90% of injected animals within 21 days. In contrast, mice injected with 4T1 FAK shRNA cells expressing only B20% level of endogenous FAK exhibited 60% survival after 60 days. Taken together with the fact that FAK catalytic activity promotes tumor metastasis, these results strongly support the therapeutic targeting of FAK in the treatment of cancer.
Materials and methods
Cells, antibodies and reagents 4T1 breast carcinoma cells were obtained from ATCC and were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). Polyclonal rabbit anti-FAK 5904 antibody (directed to FAK residues 8-27) was used for immunoprecipitates (IPs) as described (Sieg et al., 1998) . Monoclonal antibodies used for blotting were: anti-HA (16B12; Covance, Berkeley, CA, USA), anti-b-actin (AC-74; Sigma, St Louis, MO, CA, USA), anti-FAK (4.47; Upstate), anti-pTyr (4G10; UBI) and anti-GFP (B34; Covance). Rabbit polyclonal (H-140; Santa Cruz, Biotechnology, Santa Cruz, CA, USA) directed against residues 136-275 of huPA and a chicken polyclonal antibody against rat uPA (1191; American Diagnostica, Stamford, CT, USA) were used to detect mouse uPA by immunoblotting after reducing SDS-polyacrylamide gel electrophoresis (PAGE), whereas a rabbit polyclonal against rat uPA (1190; American Diagnostica, Stamford, CT, USA) was used under non-reducing conditions. 4T1 cells were grown in the presence of PP2 (20 mM), PP3 (20 mM), SP600125 (20 mM), PD98059 (2 mM), U0126 (20 mM), Wortmannin (20 mM), SB203580 (20 mM) or DMSO as a control. After 48 h, total protein lysates were blotted for cell-associated uPA levels. The pharmacological inhibitors (Calbiochem, San Diego, CA, USA) and 1 mM staurosporine solution (SIGMA) were purchased commercially. The pBabe huPA retroviral vector and pLentilox3.7 were kindly provided by Dr S Huang (Scripps, La Jolla, CA, USA) and Luk van Parijs (MIT, Cambridge, MA, USA), respectively. Stable populations of huPA-overexpressing 4T1 FAK shRNA cells were obtained by retroviral infection and puromycin selection.
Indirect immunofluorescence
Cells were fixed with 3.7% formaldehyde for 15 min, rinsed with phosphate-buffered saline (PBS) and permeabilized with PBS containing 0.5% Triton X-100 and 0.05% Tween 20 for 6 min. Cells were incubated with primary antibody overnight at 41C, washed and then treated with secondary antibody for 1 h at 371C. Coverslips were inverted onto slides using Vectamount (Vector Laboratories, Burlingame, CA, USA) and photographed at Â 40 magnification (NA ¼ 0.6; Olympus objectives).
Protein extractions
Total cell protein was extracted in radioimmunoprecipitation assay (RIPA) buffer containing 1% Triton X-100, 1% sodium deoxycholate and 0.1% SDS as described (Sieg et al., 1998) . To extract protein from mouse lungs, frozen tissue was minced into 1 mm cubes using a scalpel, and then ground in RIPA lysis buffer using a molecular grinding resin (GenoTech, St Louis, MO, USA) and a motorized drill (Dremel, Racine, WI, USA) at 41C. The cell fraction and resin were removed by centrifugation (13 000 g, 10 min) and the supernatant was used for blotting.
In vitro kinase assay For FAK, kinase assays were initiated by adding [g-32 P]ATP to immunoprecipitates and incubated at 321C for 15 min as described (Hsia et al., 2003) . Following SDS-PAGE, the gels were dried and radiolabel incorporation into FAK was quantified using a phosphorimager (Imagequant; GE Healthcare Life Sciences, Piscataway, NJ, USA).
Cell proliferation assay
For each sample, 10 4 cells were plated in twelve 35 mm wells precoated with 10 mg/ml rat tail collagen (Roche Applied Sciences, Indianapolis, IN, US) or fibronectin (Invitrogen, Carlsbad, CA, USA). Cells were grown in DMEM supplemented with 10% FBS. Two such wells were trypsinized and enumerated using hemocytometer at 24 h intervals. Each experiment was repeated twice.
Anchorage-independent survival and growth assays Anchorage-independent assays were performed using polyHE-MA-coated ultralow attachment clusters (Costar, Cambridge, MA, USA). 2 Â 10 5 cells were plated per 35 mm well, and allowed to grow for 48, 72 or 96 h. Spheroids were collected, and single cell suspension was prepared using trypsin-EDTA, and subjected to Annexin V/7-AAD staining using a kit (BD Pharmingen, San Diego, CA, USA). Cell survival was determining by the percentage of single positive apoptotic cells and double positive necrotic cells by FACS. Quadrant gates were positioned based on the autofluorescence of unstained and single stained cells in FL2 and FL3 channels (FACScan, BD, Pharmingen). For growth assay, 5 Â 10 4 cells were plated onto polyHEMA plates and photographs were taken at Â 10 magnification (NA ¼ 0.25; Nikon objectives) after 3 weeks.
Migration and invasion assays
Serum-stimulated chemotaxis assays using Millicell (12 mm diameter with 8-mm pores; Millipore) chambers were performed as described (Sieg et al., 2000) . Both sides of the membrane were coated with 10 mg/ml collagen type I (Calbiochem) and chemotaxis was stimulated by the addition of 10% FBS and enumerated after 4 h. For invasion assays, cells were placed on top of growth factor-reduced Matrigel (BD Biosciences) within Millicell chambers and enumerated after 12-24 h as described previously (Hauck et al., 2002a) . For uPA inhibitor studies, 20 mg/ml mouse PAI-1 (Calbiochem), 40 mg/ml neutralizing antibody (1190; American Diagnostica) or 40 mg/ml control antibody (Jackson ImmunoResearch labs) was added to the cells in the top chamber. Standard error of each data point represents an experiment performed in triplicate and was performed twice. Zymography A total of 3 million 4T1 cells expressing equal levels of Ad-FRNK or Ad-FRNK S1034 or stably expressing pLentilox3.7 with or without FAK shRNA were plated onto Matrigelcoated plates and grown in 0.5% serum for 48 h. Conditioned OptiMEM media (100 ml of 10 ml) were analysed by gelatin or casein-plasminogen zymography as described (Hauck et al., 2001) . Gels were stained with Coomassie blue and zones of clearing activity are presented as inverted images.
Adenoviral and lentiviral infections
Adenoviral HA-tagged FAK, F397 FAK, R454 FAK, Pronull FAK and FRNK constructs were created as described (Hsia et al., 2003 (Hsia et al., , 2005 . Adenoviral FAK and FRNK protein expressions were driven by coinfection with Ad-TA expressing the Tet transactivator. Cells were infected at a multiplicity of infection of 1 plaque-forming unit (PFU) per cell for Ad-TA and with 10 PFU/cell for Ad-FAK and Ad-FRNK. Adenoviral constructs for JNK1 and CA MEK1 were used as described (Hsia et al., 2003) . For production of lentiviruses, 293T cells were transfected by the calcium phosphate method using 20 mg plentilox3.7 or FAK shRNA construct, 10 mg of CMV-VSVg envelope vector pMD.G, 10 mg of RSV-Rev and 10 mg of packaging vector pMDL g/p RRE (Naldini et al., 1996) . Lentivirus-containing media were harvested after 48 h, filtered and used to infect 4T1 cells in the presence of polybrene (5 mg/ml) for 2 days. Infected cells expressing GFP were obtained by FACS and maintained as a pool population.
Reverse transcriptase-PCR Total RNA was extracted using 1 ml TriZol (Invitrogen) and quantified by absorbance at 260 nm. A 5 mg portion of total RNA was used as a template for reverse transcription (Invitrogen). Semiquantitative reverse transcriptase-PCR (TaqPro complete; Denville Scientific) was performed with specific primer pairs for uPA (forward 5 0 -gct cct ata atc ctg gag aga tga a-3 0 ; reverse 5 0 -acc tgt ctt ttc agc ttc ttc cct cc-3 0 ), MMP-9 (Hsia et al., 2003) and b-actin (forward 5 0 -tgt gat ggt ggg aat ggg tca g-3 0 ; reverse 5 0 -ttt gat gtc acg cac gat ttc c-3 0 ). Cycling conditions were 951C for 30 s, 551C for 40 s and 721C for 1 min (PTC-100; MJ Research). Matrix metalloproteinase-9 was analysed after 27 cycles and uPA after 42 cycles. Coamplification of b-actin was used as an internal standard for all reactions with b-actin primers present for the last 18 PCR cycles.
Anti-focal adhesion kinase short hairpin RNA The sequence used to inhibit FAK expression was cloned into pLentiLox3.7 (Rubinson et al., 2003) . Sense oligos used were 5 0 -tGA ATG GCA GCT GCT TAT CTT tca aga gAA GAT AAG CAG CTG CCA TTC ttt ttt c-3 0 (mouse), 5 0 -tGA ACC TCG CAG TCA TTT ATT tca aga gAA TAA ATG ACT GCG AGG TTC ttt ttt c-3 0 (human) and 5 0 -tGT CTC CGA ACG TGT CAC GTT tca aga gAA CGT GAC ACG TTC GGA GAC ttt ttt c-3 0 (scrambled). The 5 0 t belongs to U6 promoter, and lower letters represent components of shRNA. The underlined sequence forms the loop, and italicized run of t's is a terminator sequence. The 3 0 C was added to generate an XbaI site. Antisense oligos used were 5 0 -tcg aga aaa aaG AAT GGC AGC TGC TTA TCT Tct ctt gaA AGA TAA GCA GCT GCC ATT Ca-3 0 (mouse), 5 0 -tcg aga aaa aag aaC CTC GCA GTC ATT TAT Tct ctt gaA ATA AAT GAC TGC GAG GTT Ca-3 0 (human) and 5 0 -tcg aga aaa aag tcT CCG AAC GTG TCA CGT Tct ctt gaA ACG TGA CAC GTT CGG AGA Ca-3 0 (scrambled). Additional four nucleotides at the 5 0 end were added to generate an XbaI site. The oligos were annealed and ligated into the HpaI/XbaI site of pLentilox3.7. This vector is bicistronic and also expresses GFP from a separate CMV promoter.
Orthotopic injection, metastasis, tumor growth and apoptosis assays Care of mice, surgery and injection protocols were approved by the Scripps Institutional Animal Care and Use Committee and followed the National Institutes of Health guidelines. A total of 1 million 4T1 cells in 3 ml were injected into the T4 mammary fat pad of BALB/c mice using a Hamilton syringe. Mouse nipples served as positional cues for fat pad location. After 21 days, the body cavity of euthanized mice was analysed by whole-body GFP imaging under blue and white light illumination to acquire GFP and phase images, respectively (MetaMouse, AntiCancer Inc., San Diego, CA, USA). Lung metastasis was determined 7 days post orthotopic injection. Freshly dissected lungs were mounted in OCT (Tissue Tek, EMS) and frozen in a bath of 2-methyl butane (EMS) with dry ice. A total of 7 mm lung sections were obtained using a cryomicrotome (Leica 3050S) and were mounted onto glass slides (Super Frost Plus, Fisher). Hoechst 33342 (10 mg/ml for 15 min) was used to counterstain lung sections. Direct GFP and Hoechst 33342 fluorescence was observed using a narrow blue cube (U-MNB2; Olympus), and a wide UV cube (U-MWU2; Olympus), respectively. Photographs were taken at Â 10 (NA ¼ 0.3) and Â 20 (NA ¼ 0.5) magnification using semi-apochromatic objectives (UPLFL; Olympus) and an inverted microscope (IX51; Olympus). A neutral density filter (U722) and narrow band-width blue cube was used to reduce autofluorescence from lung tissue. Images captured at different wavelengths were merged using OpenLabs acquisition software (Improvision). Lung sections were also processed for standard hematoxylin-eosin staining as described (Hauck et al., 2002b) . For subcutaneous tumor growth assays, 10 6 4T1 cells were injected subcutaneously on the backs of shaved BALB/c mice. After 1 week, tumors were excised, weighed and frozen as described above. For the detection of apoptosis, tissue sections were analysed using a TUNEL-based cell death detection kit (Roche). TMR red-labeled nucleotides were used for the TUNEL reaction and did not interfere with GFPlabeled 4T1 cells.
Abbreviations 7-AAD, 7-amino-actinomycin D; Ad, adenoviral; CMV, cytomegalovirus; FACS, fluorescence-activated cell sorting; FAK, focal adhesion kinase; FRNK, FAK-related non-kinase; GFP, green fluorescent protein; HA, hemagglutinin; IPs, immunoprecipitates; kDa, kilodalton; MMP, matrix metalloproteinase; shRNA, short hairpin RNA; Tyr, tyrosine; uPA, urokinase plasminogen activator.
